CSCO breast cancer guideline: precise, economical and oriental

This is a preview of subscription content, log in to check access.


  1. Amin, M.B., Edge, S., Greene, F., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., et al., ed. (2017). AJCC Cancer Staging Manual. 8th ed. (Springer).

  2. Aysola, K., Desai, A., Welch, C., Xu, J., Qin, Y., Reddy, V., Matthews, R., Owens, C., Okoli, J., Beech, D.J., et al. (2013). Triple negative breast cancer—an overview. Hereditary Genets 2013, 001.

    Google Scholar 

  3. Bidard, F.C., Proudhon, C., and Pierga, J.Y. (2016). Circulating tumor cells in breast cancer. Mol Oncol 10, 418–430.

    Article  Google Scholar 

  4. Brabletz, T. (2012). To differentiate or not—routes towards metastasis. Nat Rev Cancer 12, 425–436.

    CAS  Article  Google Scholar 

  5. Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019). Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20, 806–815.

    CAS  Article  Google Scholar 

  6. Jiang, Z., Yan, M., Hu, X., Zhang, Q., Ouyang, Q., Feng, J., Yin, Y., Sun, T., Tong, Z., Wang, X., et al. (2019). Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study. JCO 37, 1001

    Article  Google Scholar 

  7. Li, X., Yang, J., Peng, L., Sahin, A.A., Huo, L., Ward, K.C., O’Regan, R., Torres, M.A., and Meisel, J.L. (2017). Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161, 279–287.

    Article  Google Scholar 

  8. Ma, F., Ouyang, Q., Li, W., Jiang, Z., Tong, Z., Liu, Y., Li, H., Yu, S., Feng, J., Wang, S., et al. (2019). Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. J Clin Oncol 37, 2610–2619.

    CAS  Article  Google Scholar 

  9. Martin, M., Holmes, F.A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S.K.L., Mansi, J., Barrios, C.H., et al. (2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol 18, 1688–1700.

    CAS  Article  Google Scholar 

  10. Masuda, N., Lee, S.J., Ohtani, S., Im, Y.H., Lee, E.S., Yokota, I., Kuroi, K., Im, S.A., Park, B.W., Kim, S.B., et al. (2017). Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376, 2147–2159.

    CAS  Article  Google Scholar 

  11. Schmid, P., Adams, S., Rugo, H.S., Schneeweiss, A., Barrios, C.H., Iwata, H., Diéras, V., Hegg, R., Im, S.A., Shaw Wright, G., et al. (2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379, 2108–2121.

    CAS  Article  Google Scholar 

  12. Somashekhar, S.P., Sepúlveda, M.J., Puglielli, S., Norden, A.D., Shortliffe, E.H., Rohit Kumar, C., Rauthan, A., Arun Kumar, N., Patil, P., Rhee, K., et al. (2018). Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board. Ann Oncol 29, 418–423.

    CAS  Article  Google Scholar 

  13. von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019). Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380, 617–628.

    CAS  Article  Google Scholar 

  14. Yang, Y., Liu, J., Peng, M., Su, F., Xie, X., Liu, Z., Wu, J., Wei, W., Zhou, D., Li, W., et al. (2020). Introduction of a multicenter online database for non-metastatic breast cancer in China. Sci China Life Sci

Download references

Author information



Corresponding authors

Correspondence to Zefei Jiang or Qiang Liu.

Additional information

Compliance and ethics

The author(s) declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, Q., Liu, J., Jiang, Z. et al. CSCO breast cancer guideline: precise, economical and oriental. Sci. China Life Sci. (2020).

Download citation